Tranilast (Rizaben), anti-chemical mediator, is useful in treating nasal allergy. We expected that the heparin level in circulating blood would change following Tranilast administration, given the known pharmacology of the drug. After the administration of Tranilast, it was expected that some parameters in coagulation-fibrinolysis system and platelet function would decrease or increase. From the above-mentioned background, α
2-plasmin inhibitor (α
2-PI) activity, antithrombin III (AT-III) activity, Factor XIII (F XIII) activity, Fibrinogen (Fg) content, Fibrinogen or fibrin degradated product (FDP) content, Factor Mu ( F 1111co) agulation activity and heparin concentration were determined in 14 patients with nasal allergy before and after the administration of Tranilast. Furthermore, platelet functions (ADP and collagen-induced aggregation) were determined. The results obtained from this study were as follows: α
2-PI activity, AT-III activity, F XIII activity, Fg content, F MI activity, ADP and collagen-induced aggregation were not significantly different before and after the administration of Tranilast. However, FDP content was significantly different before and after the administration. Heparin concentration was 0 IU/ml before and after the administration of Tranilast. From the above-mentioned results, it is suggested that the administraion of Tranilast did not affect coagulation-fibrinolysis system and platelet function.
View full abstract